ABSTRACT
Lack of established knowledge and treatment strategies, and change in work environment, may altogether critically affect the mental health and functioning of physicians treating COVID-19 patients. Thus, we examined whether treating COVID-19 patients affect the physicians' mental health differently compared with physicians treating non-COVID-19 patients. In this cohort study, an association was blindly computed between physiologically measured anxiety and attention vigilance (collected from 1 May 2014 to 31 May 31 2016) and self-reports of anxiety, mental health aspects, and sleep quality (collected from 20 April to 30 June 2020, and analyzed from 1 July to 1 September 2020), of 91 physicians treating COVID-19 or non-COVID-19 patients. As a priori hypothesized, physicians treating COVID-19 patients showed a relative elevation in both physiological measures of anxiety (95% CI: 2317.69-2453.44 versus 1982.32-2068.46; P < 0.001) and attention vigilance (95% CI: 29.85-34.97 versus 22.84-26.61; P < 0.001), compared with their colleagues treating non-COVID-19 patients. At least 3 months into the pandemic, physicians treating COVID-19 patients reported high anxiety and low quality of sleep. Machine learning showed clustering to the COVID-19 and non-COVID-19 subgroups with a high correlation mainly between physiological and self-reported anxiety, and between physiologically measured anxiety and sleep duration. To conclude, the pattern of attention vigilance, heightened anxiety, and reduced sleep quality findings point the need for mental intervention aimed at those physicians susceptible to develop post-traumatic stress symptoms, owing to the consequences of fighting at the forefront of the COVID-19 pandemic.
Subject(s)
Anxiety/psychology , Attention , COVID-19/therapy , Occupational Stress/psychology , Physicians/psychology , Reflex, Startle , Sleep , Stress Disorders, Post-Traumatic/psychology , Adult , Cluster Analysis , Female , Humans , Machine Learning , Male , Mental Health , Middle Aged , SARS-CoV-2ABSTRACT
BACKGROUND: Fasting is required by the Jewish and Islamic religions, and may sometimes be necessary for non-religious reasons as well. Very little empiric data are available on the effect of 24 hours of food and water deprivation. OBJECTIVES: To compare the effects of the dietary composition of different pre-fast meals on subjective discomfort and various other parameters of a 24 hour food and water fast. METHODS: Thirteen volunteers of both genders participated in a non-randomized crossover study. Each consumed three different equicaloric pre-fast meals in which the main source of calories was protein (49% of calories), carbohydrate (86%), or fat (69%). Weight, heart rate, blood pressure, blood and urine were tested before and after 24 hours of fasting, and the subjective evaluations of the discomfort during the three fasts were compared. RESULTS: After the protein-rich meal greater discomfort and more side effects were reported. Weight and blood pressure decreased at the end of the fasts that followed each of the three meals; heart rate increased after the high fat and carbohydrate meals but not after the protein meal. The main laboratory findings were a 40% increase in blood urea nitrogen and higher urine osmolarity after the protein-rich meal than after the other meals. CONCLUSION: A protein-poor pre-fast meal is likely to be followed by easier fasting.
Subject(s)
Diet , Fasting , Hunger/drug effects , Thirst/drug effects , Adult , Blood Glucose/drug effects , Cholesterol/blood , Cross-Over Studies , Dietary Carbohydrates/administration & dosage , Dietary Carbohydrates/pharmacology , Dietary Fats/administration & dosage , Dietary Fats/pharmacology , Dietary Proteins/administration & dosage , Dietary Proteins/pharmacology , Female , Humans , Male , Middle AgedABSTRACT
AIM: To assess the immunogenicity of hepatitis B vaccine in preterm and term infants, given in a sequence of three doses beginning soon after birth. METHOD: The immunogenicity of hepatitis B vaccine was assessed in 176 preterm infants (< 35 weeks of gestation), immunised soon after birth, and compared with that in 46 term infants. Titres of hepatitis B antibodies were determined one to two months after the third vaccine. The significance of the differences between the term and preterm groups was determined using Student's t test. RESULTS: A similar proportion of infants in both preterm and term groups attained protective titres of hepatitis B antibodies (88.7% vs 93.4%, respectively; p = NS). However, the term infants had a higher geometric mean titre of antibodies after the third vaccine than did the preterm infants (701.2 (745.0) vs 469.1 (486.2) mU/ml, respectively; p < 0.03). CONCLUSION: Hepatitis B vaccine is effective in most preterm infants when given soon after birth. It may be advisable to determine the immune response at 12-24 months of age to booster the non-responders.
Subject(s)
Hepatitis B Vaccines/immunology , Hepatitis B/prevention & control , Infant, Premature/immunology , Vaccines, Synthetic/immunology , Antibody Formation , Case-Control Studies , Chi-Square Distribution , Female , Hepatitis B Vaccines/administration & dosage , Humans , Immunization Schedule , Infant , Infant, Newborn , Male , Vaccines, Synthetic/administration & dosageABSTRACT
BACKGROUND: Most of the licensed hepatitis B vaccines produced by recombinant DNA contain the S protein component of the hepatitis B virus surface antigen particle but lack two important components, Pre-S1 and Pre-S2. These components have recently been shown to play an important immunogenic role by enhancing the hepatitis B surface antibody (anti-HBs) titers, stimulating response and circumventing genetic nonresponsiveness. OBJECTIVE: To assess safety, tolerability and immunogenicity in neonates of a novel recombinant HBV vaccine (Bio-Hep-B) containing the S, Pre-S1 and Pre-S2 components compared with a licensed recombinant vaccine (Engerix-B) containing the S component only. METHODS: Healthy neonates were randomized to receive either Bio-Hep-B (2.5 micrograms/dose) or Engerix-B (10 micrograms/dose) at ages < 24 h, 1 month and 6 months. Blood was obtained at ages 0, 1, 7 and 12 months. Tolerability was assessed by diary cards filled by the parents for 5 successive days after immunization. Immunogenicity was assessed by determination of anti-HBs antibody. RESULTS: Of 205 neonates 153 were in the Bio-Hep-B group and 52 were in the Engerix-B group. Both vaccines were well-tolerated and all infants became seroprotected (anti-HBs > 10 mIU/ml). After the first dose a significantly higher proportion of neonates seroconverted in the Bio-Hep-B group than in the Engerix-B group (83% vs. 34%; P < 0.001); this difference in seroresponse was even more pronounced for those achieving seroprotective concentrations (> 10.0 mIU/ml) after the first dose: 54% vs. 7%, respectively (P < 0.001). Geometric mean concentrations were significantly higher at all points in the Bio-Hep-B group. CONCLUSION: Both vaccines were well-tolerated and immunogenic. Bio-Hep-B, despite its low dose, was significantly more immunogenic and elicited more rapid antibody response. This finding has implication for future vaccine programs in regions where maternal screening for hepatitis B virus surface antigen and administration of hepatitis B immunoglobulin are not routinely practiced at birth for infants of hepatitis B virus carrier mothers.
Subject(s)
Hepatitis B Surface Antigens/immunology , Hepatitis B Vaccines/immunology , Protein Precursors/immunology , Vaccines, Synthetic/immunology , Female , Hepatitis B Antibodies/blood , Hepatitis B Vaccines/adverse effects , Humans , Immunoglobulins/immunology , Infant, Newborn , Male , Prospective Studies , Vaccines, Synthetic/adverse effectsABSTRACT
Erythropoietin (rHuEPO) therapy has been shown to be beneficial in preventing and treating anaemia of prematurity and to decrease the need for blood transfusions. There is, however, only scanty data on the effect of rHuEPO therapy on iron metabolism. We studied 29 preterm infants (age 34 +/- 14 days) who were randomly assigned to receive either rHuEPO 900 U kg-1 week-1 with 6 mg kg-1 day-1 of iron for 4 weeks (n = 15) or no therapy. The following parameters were evaluated and compared between and within groups at the beginning, during and at the end of the study: Haematocrit (SI), reticulocytes (10(9) micrograms l-1), serum ferritin (microgram 1-1) and iron (mumol l-1). The results were as follows. At the baseline, erythropoietin levels were similar in both groups: 7.2 +/- 5.6 versus 6.2 +/- 3.2 mU ml-1 (NS). In the treated infants the haematocrit remained stable during the study and was significantly higher than in the control group by the end of the study: 0.34 +/- 0.03 versus 0.28 +/- 0.05 (p = 0.001). rHuEPO therapy increased the reticulocyte count from 130 +/- 70 to 430 +/- 200 (p = 0.0002). However, rHuEPO therapy depleted both serum ferritin and iron levels from 321 +/- 191 to 76 +/- 58 micrograms l-1 (p = 0.04) and from 18 +/- 5 to 13 +/- 4 mumol l-1 (p = 0.03), respectively. We conclude that rHuEPO therapy prevented anaemia and its sequelae; however, serum ferritin and iron levels were depleted. We suggest that the effect of rHuEPO may be further increased by higher iron supplementation.
Subject(s)
Anemia, Neonatal/therapy , Erythropoietin/therapeutic use , Ferritins/blood , Ferrous Compounds/therapeutic use , Infant, Premature, Diseases/therapy , Recombinant Proteins/therapeutic use , Anemia, Neonatal/blood , Body Weight , Combined Modality Therapy , Hematocrit , Humans , Infant , Infant, Newborn , Infant, Premature, Diseases/blood , Infant, Very Low Birth Weight , Iron/blood , Reticulocyte CountABSTRACT
The dilemma of when to deliver preterm or growth-restricted fetuses with abnormal monitoring is faced by all those treating such patients. Current noninvasive tests for fetal well-being have relatively high false-positive rates. Cordocentesis allows the clinician to directly analyze fetal blood and determine whether the fetus is truly in distress, is suffering from aneuploidy, or is plagued by infection. However, with improved neonatal care, otherwise normal infants of birth weight greater than 1500 gm have very low morbidity and mortality rates and any delay in delivery offered by cordocentesis is probably not justified. It is in the fetus whose estimated weight is below 1500 gm that cordocentesis should be used. If the results are normal, expectant management and the administration of corticosteroids will allow for pulmonary maturation and a more favorable outcome.
Subject(s)
Cordocentesis , Fetal Distress/diagnosis , Fetal Growth Retardation , Fetal Monitoring , Infant, Very Low Birth Weight/physiology , Obstetric Labor, Premature , Cordocentesis/adverse effects , Female , Fetal Distress/blood , Fetal Growth Retardation/physiopathology , Humans , Infant Mortality , Infant, Newborn , Infant, Premature , Predictive Value of Tests , PregnancyABSTRACT
Prenatal sonographic presentation of Hirschsprung's disease has been considered non-specific and uncommon. This report presents a second-trimester fetus with an aganglionic colon and ileum diagnosed by the sonographic presentation of dilated fetal bowel loops, increased abdominal circumference, and mild polyhydramnios. The prenatal sonographic diagnosis of Hirschsprung's disease helped to expedite early neonatal treatment.
Subject(s)
Colon/innervation , Hirschsprung Disease/diagnostic imaging , Ileum/innervation , Myenteric Plexus/abnormalities , Ultrasonography, Prenatal , Adult , Colon/diagnostic imaging , Colon/surgery , Female , Ganglia/abnormalities , Ganglia/cytology , Gestational Age , Hirschsprung Disease/surgery , Humans , Ileum/diagnostic imaging , Ileum/surgery , Myenteric Plexus/cytology , PregnancyABSTRACT
To compare the effects of intermittent and continuous feedings on pulmonary function, we studied 24 very low birth weight neonates (mean +/- SD: birth weight, 1.2 +/- 0.3 kg; gestational age, 30.5 +/- 1.1 weeks) at 2 to 4 weeks of age. All infants had a previous diagnosis of respiratory distress syndrome but no subsequent diagnosis of bronchopulmonary dysplasia. Pulmonary mechanics were measured before the beginning of intermittent or continuous feedings and 10 minutes after each meal was completed. Twelve infants were randomly assigned to intermittent and 12 to continuous feedings. These infants had similar birth weight, gestational age, study age, and baseline lung function. After intermittent feedings, there was a significant decrease in tidal volume (38%), minute ventilation (44%), and dynamic compliance (28%), whereas pulmonary resistance increased significantly (100%). In comparison, the pulmonary function data remained unchanged after continuous feedings. These data demonstrate that intermittent feeding of very low birth weight infants can lead to airflow and respiratory instability. These adverse effects appear to be dependent on the rate that feedings are administered. A slower pace of feeding may be more advantageous for infants prone to respiratory instability.
Subject(s)
Enteral Nutrition/methods , Infant, Low Birth Weight/physiology , Respiratory Mechanics , Humans , Infant, Newborn , Maximal Expiratory Flow-Volume Curves , Respiratory Distress Syndrome, Newborn/physiopathology , Tidal VolumeSubject(s)
Blood Glucose/analysis , Hematocrit , Reagent Strips/standards , Humans , Infant, NewbornABSTRACT
A model utilizing human umbilical cord blood was used to screen for hypoglycemia in a simulated neonatal situation. The aims of the study were to assess the effect of increasing Hct concentration on Dextrostix readings, and to determine whether plasma samples, in contrast to conventional whole blood samples, were acceptable for Dextrostix determinations in selected cases. Dextrostix readings were determined on 65 whole blood samples of varying Hct, and on plasma specimens, 48 of which were paired with whole blood samples. The results were compared with plasma true glucose values. Plasma Dextrostix readings correlated well with true glucose values throughout the entire Hct range (r = .94, slope = 1.16). Whole blood Dextrostix readings, on the other hand, were Hct-dependent and, with increasing Hct values, became falsely low. As a result, a Hct values greater than 70%, whole blood Dextrostix readings were less than 50% of the true glucose value (r = .94, slope = 0.45). Plasma Dextrostix determinations may offer an accurate means of screening for neonatal hypoglycemia in asymptomatic infants with high Hct, pending laboratory glucose results.
Subject(s)
Blood Glucose/analysis , Chromogenic Compounds , Glucose Oxidase , Hematocrit , Hypoglycemia/blood , Peroxidases , Reagent Strips , Fetal Blood/analysis , Humans , Infant, Newborn , Plasma/analysis , Predictive Value of TestsABSTRACT
Following previous observations that medium chain triglycerides (MCT) are absorbed from the stomach of suckling rats, this study was devoted to studying absorption of MCTs in human infants. Four groups of patients were studied: (a) infants suffering from pyloric stenosis, (b) premature infants, (c) children suffering from cystic fibrosis, (d) infants with miscellaneous conditions. Infant formulae with known amounts of MCT were introduced by gastric tube and samples were removed at 0, 20, 40, and 60 min. In patients with pyloric stenosis there was an 18.1% decrease in MCT during the first 20 min. No significant changes in MCT took place during the subsequent 40 min. A similar response was observed in the group of premature infants. Older infants with miscellaneous diagnoses and children with cystic fibrosis showed an even rate of disappearance of MCT during the 60-min test period, and approximately 30% of the original MCTs present disappeared during this period. We conclude that MCTs are absorbed in the stomach of infants and children. Absorption appears to improve with age. Because MCT are an important constituent of formulae for premature infants and children with defects of small intestinal digestion and absorption of fat, these observations have practical implications.
Subject(s)
Cystic Fibrosis/metabolism , Gastric Mucosa/metabolism , Infant, Premature/metabolism , Pyloric Stenosis/metabolism , Triglycerides/pharmacokinetics , Humans , Infant , Infant Food , Infant, Newborn , Time FactorsABSTRACT
In view of the technical difficulties inherent in using stool fat estimations as a parameter of malabsorption, we used a fatty meal absorption test. Children under investigation for failure to thrive were divided into two groups, those having a normal stool fat output (less than 3.2 g/day) constituting the control group, and those having steatorrhea. After a fatty meal containing 25 g of margarine and 25 g of butter fat, we measured the rise of serum triglycerides and chylomicrons hourly for 5 h. Serum triglyceride rise of less than 100 mg/dl or less than 100% above basal values and the appearance of less than 7% of chylomicrons were considered pathological. Of our control group 95% had a normal rise of triglycerides; and 96% of our patients with steatorrhea had an abnormal rise. This test was more reliable than the two-point triglyceride test previously described for the diagnosis of fat malabsorption. The fatty meal test as described here is considered to be a useful test of absorptive function.